October 23, 2026 09:17 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Tiger Shroff, not Salman Khan, was the main target, probe reveals shocking details | Dammam airport attack: Indian killed, two compatriots injured as Saudi Arabia faces fresh strikes | ‘Among others’: Macron takes swipe at Trump over France unrest, calls foreign leaders’ remarks ‘stupid’ | ‘Specific threat-related inputs’: Delhi Police blocks Diljit Dosanjh’s Delhi concert | ‘Barbaad kare alfaz mere’: Ranbir Kapoor apologises for Dussehra gaffe in Kolkata | Delhi court releases CJP's Saurav Das and Ashutosh Ranka after 7 days in custody | ‘We are seeing what is happening outside our country’: Delhi HC judge’s remark as CJP leaders Saurav Das and Ashutosh Ranka withdraw custody plea | Salman Khan was the original target? Tiger Shroff firing probe reveals shocking twist | ‘UN experts are an oxymoron’: Marco Rubio takes swipe at UN, refuses to comment on India's protests | ‘US ties with no country come at India's expense’: Marco Rubio addresses concerns over Pakistan, China
Japan I Covid19
Image Cr: Unsplash

Japan approves home-made Covid-19 cure for emergency use

| @indiablooms | Nov 24, 2022, at 06:44 pm

Tokyo/UNI: The Japanese Health Ministry has authorised the island nation's first locally made COVID-19 oral treatment, Xocova, for emergency use.

This emergency approval was granted on the anticipated efficacy of Xocova and the acceptability of its safety profile based on the results obtained through the Phase 2 part (497 cases including the Phase 2a and Phase 2b parts combined) and the Phase 3 part (1,821 cases) of the Phase 2/3 study.

The pill was developed by Osaka-based pharmaceutical firm Shionogi & Co to treat coronavirus patients after they develop initial symptoms, such as fever, cough, a sore throat, a runny nose, and fatigue.

Xocova is an oral antiviral agent administered once daily for five days that suppresses the replication of SARS-CoV-2 by selectively inhibiting the viral 3CL protease.

It has been proven the most effective when administered during the first three days of symptoms starting.

The drug is known to reduce the viral load to three percent when taken on day four, and is not recommended for use during pregnancy.

Shionogi had filed for manufacturing and sales approval on Feb. 25, 2020.

The company said it had enough pills to treat one million people, and the drug will hit the shelves in Dec.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.